

Excitement about the effectiveness and availability of blood biomarker testing for Alzheimer’s disease (AD) has created confusion around whether there’s still a need for other important tools, like cognitive screening. The answer is simple. Cognitive screening is integral to monitoring brain function and identifying impairment in older adults. (But even cognitive screening makers like Neurotrack […]
Read moreIn a significant milestone for Alzheimer’s disease treatment, the U.S. Food and Drug Administration (FDA) recently approved the groundbreaking new drug, Leqembi. The medication is poised to bring new hope and treatment options to the more than 55 million people worldwide currently diagnosed with dementia or Alzheimer’s. To better understand Leqembi’s potential impacts, let’s unpack […]
Read moreResearch has shown that the majority of Americans would want to know if they have Alzheimer’s disease (AD) so that they could take advantage of early treatments. Yet, most people experiencing cognitive issues are reluctant to share their concerns with their primary care physician (PCP), the providers on the front lines of diagnosing AD. While […]
Read moreWhen the brilliant and talented Tina Turner passed after a long battle with kidney disease, one of her biggest regrets came to light. She hadn’t understood the link between high blood pressure and kidney health before it was too late, and she desperately wanted to raise awareness. We don’t get warnings like this from people […]
Read moreCognitive care is no exception to the racial imbalances Black, Hispanic, Asian, and Native American individuals experience in healthcare. It is a well known fact that two-thirds of the American population living with Alzheimer’s are women, irrespective of race. Yet, they have also been historically underrepresented in clinical trials and face more barriers to accessing […]
Read moreBrain health, Alzheimer’s disease, and the hormonal changes women experience around menopause all intersect. It’s an important roundtable discussion from Neurotrack’s CEO and the experts at Midi Health.
Read moreWith almost 50 million people worldwide affected by dementia—and Alzheimer’s disease the likely cause in 60% to 80% of these cases—detection and care is at a critical juncture. Despite high prevalence of cognitive disease, significant barriers, healthcare provider burnout, and systemic bottlenecks all interfere with their identification and treatment. By exploring common problems in cognitive […]
Read moreHaunted by the lethal prospect of cognitive disease, I saw huge advances being made in treating cardiovascular conditions, diabetes, and cancer through screening and behavior change, and had a spark. It seemed that brain health could benefit from the same approach. But there was little medical infrastructure to make it happen.
Read moreNew hire to drive business expansion amid exciting advances in Alzheimer’s treatment and care (PRESS RELEASE) Neurotrack, the leader in science-backed cognitive health solutions, announced Shawn Lemerise as its first Chief Growth Officer to support the company’s expanding business. With more than 20 years of healthcare experience, Shawn brings his expertise in the health system and provider […]
Read moreThrough technological innovation, policy reform, and greater patient demand, PCPs are now in a position to integrate a quick cognitive screening into their practice offerings.
Read more